| Bulletin # | Date | Topics | Type | | BT202164 | 07/29/2021 | IHCP announces limited opportunity for new independent external reviews | All |
| BT202163 | 07/27/2021 | IHCP revises the NPI reporting requirements for enrolling providers | All |
| BT202162 | 07/27/2021 | Pharmacy updates approved by Drug Utilization Review Board July 2021 | Pharmacy/Prescribing |
| BT202161 | 07/27/2021 | IHCP rescinds temporary provider enrollment COVID policies | All |
| BT202160 | 07/22/2021 | CMS clarifies that MCEs can continue to bypass NCCI edit causing NOP claims to deny | All |
| BT202159 | 07/20/2021 | OMPP announces Targeted Probe Education program | All |
| BT202158 | 07/20/2021 | IHCP updates Outpatient Fee Schedule | All |
| BT202157 | 07/13/2021 | IHCP aligns PA criteria for nusinersen (Spinraza) | Ordering, Prescribing, or Referring; Pharmacy/Prescribing; Physician/Practitioner |
| BT202156 | 07/08/2021 | Coverage and billing information for the July 2021 HCPCS code update | All |
| BT202155 | 07/08/2021 | OMPP announces due dates and reinstatement penalties for LTC providers | Nursing Facility, Long-Term Care, ICF/IID |
| BT202154 | 07/06/2021 | IHCP informs pharmacy providers of the billing specifications for prescription origin codes | Pharmacy, Prescribing |
| BT202153 | 07/06/2021 | Providers may now request palivizumab RSV prophylaxis for high-risk IHCP members | Pharmacy, Prescribing |